Purchase Order 75N94023P00460
Award Date 6/30/23
Potential Completion Date 9/30/25
Potential Value $238K
Funding Federal Agency
Contracting Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Tonawanda, NY 14150, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The National Institutes of Health's National Institute of Diabetes and Digestive and Kidney Diseases has awarded a $15,400 firm fixed price purchase order to Pine Pharmaceuticals LLC. The contract is for the delivery of 6,6 D2Glucose intravenous stable isotopes to support metabolic research studies being conducted by NIDDK in Tonawanda, New York. Pine Pharmaceuticals is an FDA-registered 503B outsourcing facility specializing in high-quality pharmaceutical compounds and repackaged products, with...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $91,897.70 firm fixed-price delivery order to Pine Pharmaceuticals LLC for the procurement of intravenous stable isotope glucose (6,6 deuterated glucose) to support metabolic research. The contract, awarded on December 18, 2025, with an ultimate completion date of May 31, 2026, was issued without a set-aside designation. Pine Pharmaceuticals, an FDA-registered 503B outsourcing facility located in Tonawanda,...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the Department of Health and Human Services, awarded a $44,606.40 firm fixed-price purchase order to Pine Pharmaceuticals LLC, a small business contractor located in Tonawanda, New York. The contract is for the acquisition of intravenous stable isotopes, specifically D5 glycerol and 6,6 D2-glucose, to support metabolic research. This award is not associated with a larger contract vehicle. The contract has a...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded a delivery order valued at $69,466.32 to Pine Pharmaceuticals LLC on August 14, 2025, for the provision of intravenous stable isotope glucose (6,6 deuterated glucose) to support metabolic research initiatives. This non-severable delivery order, structured as a firm fixed-price contract, is scheduled for completion by May 31, 2026, with performance taking place at Pine Pharmaceuticals' facility in Tonawanda, New York. No...
- This is a $125,812.80 firm-fixed-price purchase order awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to Pine Pharmaceuticals LLC, a for-profit limited liability company. The contract is for the acquisition of intravenous stable isotopes, specifically 6,6 deuterated glucose and d5 glycerol, to support metabolic research conducted by NIDDK. The contract was awarded on a non-competitive, sole-source basis, as Pine Pharmaceuticals is the only approved...
- This is a firm fixed-price purchase order awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the U.S. Department of Health and Human Services, to Pine Pharmaceuticals LLC, a for-profit limited liability company located in Tonawanda, New York. The $12,580.80 contract is for the acquisition of intravenous stable isotopes, which are specialized pharmaceutical compounds used in metabolic and clinical research studies. Pine Pharmaceuticals is an...
- This is a $27,384.76 firm fixed-price purchase order awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a civilian agency within the U.S. Department of Health and Human Services, to Pine Pharmaceuticals LLC, a for-profit limited liability company located in Tonawanda, New York. The contract is for the provision of 3 batches/shipments of 60 units each of the intravenous stable isotope D5 glycerol, which is required for metabolic research studies conducted...
- This is a $81,714.96 firm fixed-price delivery order contract awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a civilian agency within the U.S. Department of Health and Human Services, to Pine Pharmaceuticals LLC, a for-profit limited liability company located in Tonawanda, New York. The contract is for the provision of intravenous stable isotope glucose (D5 glycerol) to support metabolic research. The contract has an ultimate completion date of April 30,...
- This is a $22,303.20 firm fixed-price purchase order awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a civilian agency within the Department of Health and Human Services (HHS), to Pine Pharmaceuticals LLC, a small business based in Tonawanda, New York. The contract is for the acquisition of an intravenous stable isotope, which is likely a specialized pharmaceutical product used in metabolic and clinical research studies conducted by NIDDK and other HHS...
- This is a firm-fixed-price purchase order awarded by the National Institute of Child Health and Human Development (NICHD), an agency within the U.S. Department of Health and Human Services (HHS), to Pine Pharmaceuticals LLC for the procurement of intravenous stable isotope (6,6 D2-Glucose) for metabolic research. The $138,712.14 contract has an ultimate completion date of November 2, 2024 and was awarded on a sole-source basis without a small business set-aside. Pine Pharmaceuticals is an...